

HepaRG細胞 論文・ポスターのご紹介

Cytochromes p450

- 1) HepaRG: a novel human differentiated hepatoma cell line exhibiting high levels of inducible CYP450s and GSTs enzymes useful for pharmacological and toxicological applications.
Cerec V., Corlu. A., Glaise D., Guguen-Guillouzo C., Gripon P., Guyomard C., Boissier C.
HUG MEETING. 2004. Nov. **Poster**
- 2) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells.
Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, Guguen-Guillouzo C, Guillouzo A.
Drug Metab Dispos. 2006 Jan;34(1):75-83.
- 3) Characterisation of cytochrome P450 induction in HepaRG Cells.
Persson K.P. and Andersson T.B.
HUG meeting 2006. **Poster**
- 4) HepaRG Cells as an in vitro model for evaluation of cytochrome P450 induction in humans.
K P Kanabratt and T. B. Andersson
Drug Metab Dispos 2008. Jan;36(1) :137-145.
- 5) Functional expression of Cytochrome P450 enzymes in human hepatoma HepaRG cell line.
Miia T., Ari T., Claire G., Jouko U., Christophe C., Jukka H., Guguen-Guillouzo C., Andre G., Olavi P.
P450 meeting 2007. **Poster**
- 6) Epinephrine induces an inflammatory response in human hepatoma HepaRG cells.
Aninat C., Descheemaeker P.-N., Seguin P., Morel F., Malledant Y., Guillouzo A.
ISSX Meeting, 2007. **Poster**
- 7) Evaluation of multiple in vitro systems (PXR reporter gene assay, Fa2N-4 cells, HepaRG cells and Human hepatocytes) to Determine CYP3A4 induction potential of new chemical entities in drug discovery.
Geraldine A.H., Jane K., Sara O., Suzette H., Karen R.S., Denis P., Etienne L., David S., George Z., Maria R., Tommy B.A., Payal P., David A., Rob R., Patrick B., Dermot M.
ISSX Meeting .2008. **Poster**
- 8) HepaRG cells as an in vitro model for cytochrome P450 induction and drug metabolism.
Kajsa P. Kanebratt and Tommy B. Andersson,
ISSX meeting 2008. **Poster**
- 9) Human HepaRG Hepatocytes: Long-term functional stability & responsiveness to prototypical inducers.
R Li, S. Antherieu , M. Turpeinen , S. Camus , P. Fritayre, B. Shevchenko, A. Gullouzo , N. Rougier. **Poster**
- 10) Catecholamines induce an inflammatory response in human hepatocytes.
Aninat C, Seguin P, Descheemaeker PN, Morel F, Malledant Y, Guillouzo A,
Crit Care Med. 2008 Mar ; 36(3): 848-854.
→ 参照: 6) Epinephrine induces an inflammatory response in human hepatoma HepaRG cells.
- 11) Evaluation of HepaRG Cells as an in vitro model for human drug metabolism studies.
kajsa P.Kanebaratt and Tommy B. Andersson.
Drug.Metab. Disposition.2008 Oct;36(7):1444-1452.
- 12) Dose- and time-dependent effects of Phenobarbital on gene expression profiling in human hepatoma HepaRG cells.
Lambert C., Spire C., Claude N., Guillouzo A.
Toxic.Appl.Pharmacol.2009 Feb 1;234(3) :345-360.

- 13) Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells.
McGinnity DF, Zhang G, Kenny JR, Hamilton GA, Otmani S, Stams KR, Haney S, Brassil P, Stresser DM, Riley RJ.
Drug.Metab. Dispos.2009 Jun;37(6):1259-1268.
→ 参照: 7) Evaluation of multiple in vitro systems (PXR reporter gene assay, Fa2-N4 cells, HepaRG cells and Human hepatocytes) to Determine CYP3A4 induction potential of new chemical entities in drug discovery.)
- 14) Functional expression, inhibition and induction of CYP enzymes in HepaRG cells.
Tu rpeinen M., Tolonen A, Chesne C., Guillouzo A., Usitalo J., Pelkonen O.
Toxicol. in Vitro.2009 Jun ;23 (4):748-753.
→ 参照: 5) Functional expression of Cytochrome P450 enzyme in human hepatoma HepaRG cell line.
- 15) Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1 alpha involvement in CYP3A4 repression.
Legendre C, Hori T, Loyer P, Aninat C, Isida S, Glaise D, Lucas-Clerc C, Boudjema K, Guguen-Guillouzo C, Gorlu A, Morel F.
Eur J Cancer. 2009 Nov; 45(16) :2882-2892.
- 16) In vitro model for the prediction of clinical CYP3A4 induction using HepaRG cells.
Kaneko A, Kato M, Sekiguchi N, Mitsui T, Takeda K, Aso Y.
Xnobiatica. 2009 Nov ;39(11): 803-810.
- 17) In Vitro and in Vivo induction of Cytochrome P450: A survey of the Current Practices and Recommendations: A Pharmaceutical Research and manufactures of America Perspective.
Chu V., Einolf H.J., Evers R., Kumar G., Moore D., Ripp S., Silva J., Sinha V., Sinz M., Skerjanec A.
Drug.Metab. Disposition.2009 ;37 (7): 1339-1353.
- 18) Quantity Production Of Metabolites Using HepaRG® Human Hepatic Cells
Chesne C., Annand R., Steen D., Guillet F., Tsaïoun K.
ISSX Meeting 2009 **Poster**
- 19) Nuclear Receptor Signaling in HepaRG Cells.
Dan E. Brobst and Jeff L. Staudinger.
ISSX Meeting 2009. **Poster**
- 20) Evaluation Of HepaRG Cells For Determining CYP Induction In Drug Discovery.
Denton R., Soars M., Haney S., McGinnity D., Riley R.
ISSX Meeting 2009. **Poster**
- 21) HepaRG Cells Express Genes More Similar to Human Hepatocytes than HepG2 Cells.
Hart S.N., Li Ye, Nakamoto K., Subileau Eva-anne, Steen D., Zhong Xiao-bo.
ISSX Meeting 2009. **Poster**
- 22) Simultaneous Determination of Cyp450 Induction and Metabolism in Metabolically Competent Human Hepatocyte Cell Line HepaRG.
Annand R.R., Steen D., Jacewicz M., Tsaïoun K., Chesne C.
ISSX Meeting 2009. **Poster**
- 23) Stable Expression, Activity, and Inducibility of Cytochromes P450 in Differentiated HepaRG Cells.
Antherieu S, Chesne C, Li R, Camus S, Lahoz A, Picazo L, Turpeinen M, Tolonen A, Uusitalo J, Guguen-Guillouzo C, Guillouzo A.
Drug Metab Dispos. 2010; 38(3): 516-525.
- 24) A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.
Hart S.N., Li Ye, Nakamoto K., Subileau EA., Steen D., Zhong XB.
Drug Mtab. Dispos.2010 Jun; 38 (6): 988-994.
→ 参照: 21) HepaRG Cells Express Genes More Similar to Human Hepatocytes than HepG2 Cells.

- 25) HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro.
Lübberstedt M, Müller-Vieira U, Mayer M, Biemel KM, Knöspel F, Knobloch D, Nüssler AK, Gerlach JC, Zeilinger K.
J Pharmacol Toxicol Methods. 2011 Jan-Feb; 63(1): 59-68.
- 26) Involvement of aryl hydrocarbon receptor in basal and 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced expression of target genes in primary human hepatocytes.
Le Vee M, Jouan E, Fardel O.
Toxicol In Vitro. 2010 Sep; 24(6): 1775-1781.
- 27) General review on in vitro hepatocyte models and their applications.
Guguen-Guillouzo C, Guillouzo A.
Methods Mol Biol. 2010;640:1-40.
- 28) The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies.
Marion MJ, Hantz O, Durantel D.
Methods Mol Biol. 2010; 640:261-272.
- 29) The application of HepRG cells in evaluation of cytochrome P450 induction properties of drug compounds.
Andersson TB.
Methods Mol Biol. 2010; 640:375-387.
- 30) The Chinese Herbal Medicine Sophora Flavescens Activates Pregnane X Receptor.
Wang L, Li F, Lu J, Li G, Li D, Zhong XB, Guo GL, Ma X.
Drug Metab Dispos. 2010; 38 (12): 2226-2231.
- 31) Biotransformation pathway maps in WikiPathways enable direct visualization of drug metabolism related expression changes.
Danyel G.J.Jennen, Stan Gaj., Pieter J. Giesbertz, Joost H.M.van Delft, Chris T. Evelo, Jos C.S. Kleinjans.
Drug Discovery Today. 2010.Oct 15(19/20):851-858.
- 32) The Use of HepaRG and Human Hepatocyte Data in Predicting CYP Induction Drug-Drug Interactions via Static Equation and Dynamic Mechanistic Modelling Approaches.
Grime K, Ferguson DD, Riley RJ.
Curr Drug Metab. 2010 Dec; 11(10): 870-885.
- 33) Critical selection of reliable reference genes for gene expression study in the HepaRG cell line.
Ceelen L, De Spiegelaere W, David M, De Craene J, Vinken M, Vanhaecke T, Rogiers V.
Biochem Pharmacol. 2011 Mar 15; 81(10) :1255-1261.
- 34) Cytochrome P450 (CYP) dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional(3D) bioreactor.
Darnell M, Schreiter T, Zeilinger K, Urbaniak T, Soderdahl T, Rossberg I, Dillner B, Berg AL, Gerlach J, Andersson TB.
Drug Metab Dispos. 2011 Jul; 39(7):1131-1138.
- 35) Prediction of clearance from the HepaRG cell system: comparison with human hepatocytes for a range of substrates.
Ugo Zanelli, Pasquale Caradonna, David Hallifax, James Brian Houston.
ISSX Meeting 2010. **Poster**
- 36) The HepaRG cell line is suitable for bioartificial liver application.
Hoekstra R, Nibourg GA, van der Hoeven TV, Ackermans MT, Hakvoort TB, van Gulik TM, Lamers WH, Elferink RP, Chamuleau RA.
Int J Biochem Cell Biol. 2011 Oct; 43(10):1483-1389.
- 37) Expression systems of cytochrome P450 proteins in studies of drug metabolism in vitro.
Pawłowska M, Augustin E.
Postepy Hig Med Dosw (Online). 2011 Jun 17;65:367-376. Polish.
- 38) Predictive Utility of In Vitro Rifampin Induction Data Generated in Fresh and Cryopreserved Human Hepatocytes, Fa2N-4 and HepaRG Cells.
Templeton IE, Houston JB, Galetin A.
Drug Metab Dispos. 2011 Oct; 39(10): 1921-1929.

- 39) Inter-individual Variability in Gene Expression Profiles in Human Hepatocytes and Comparison with HepaRG Cells.
Rogue A, Lambert C, Spire C, Claude N, Guillouzo A.
Drug Metab Dispos. 2011 Jan ; 40(1) : 151-158.
- 40) The Role of CYP3A4 mRNA Transcript with Shortened 3'-UTR in Hepatocyte Differentiation, Liver Development, and Response to Drug Induction.
Li D, Gaedigk R, Hart SN, Leeder JS, Zhong XB.
Mol Pharmacol. 2012 Jan; 81(1): 86-96.
- 41) Comparison of Cryopreserved HepaRG Cells with Cryopreserved Human Hepatocytes for Prediction of Clearance for 26 Drugs.
Zanelli U, Caradonna NP, Hallifax D, Turlizzi E, Houston JB.
Drug Metab Dispos. 2012 Jan; 40(1): 104-110.
- 42) Characterization of human cytochrome P450 induction by pesticides.
Khaled A., Virpi L., Petri R., Jenni K., Paavo H., Sampo M., Olavi P., Jukka H.,
Toxicology. 2012 Mar 29;294(1):17-26.
- 43) Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins.
Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, Atienzar FA.
Cell Biol Toxicol. 2012 Apr;28(2):69-87.
- 44) The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human.
Andersson TB, Kanebratt KP, Kenna JG.
Expert Opin Drug Metab Toxicol. 2012 Jul; 8(7): 909-920.
- 45) Co-cultures of enterocytes and hepatocytes for retinoid transport and metabolism.
Rossi C, Guantario B, Ferruzza S, Guguen-Guillouzo C, Sambuy Y, Scarino ML, Bellovino D.
Toxicol In Vitro. 2012 Apr 20. in Article.
- 46) Optimization of the **HepaRG** cell model for drug metabolism and toxicity studies.
Anthérieu S, Chesné C, Li R, Guguen-Guillouzo C, Guillouzo A
Toxicol In Vitro. 2012 May 27
- 47) Nanofibrillar cellulose hydrogel promotes three-dimensional liver cell culture.
Bhattacharya M, Malinen MM, Lauren P, Lou YR, Kuisma SW, Kanninen L, Lille M, Corlu A, Guguen-Guillouzo C, Ikkala O, Laukkanen A, Urtti A, Yliperttula M.
J Control Release. 2012
- 48) In Vitro Evaluation of Major In Vivo Drug Metabolic Pathways Using Primary Human Hepatocytes and HepaRG Cells in Suspension and a Dynamic Three-Dimensional Bioreactor System.
Darnell M, Ulvestad M, Ellis E, Weidolf L, Andersson TB.
J Pharmacol Exp Ther. 2012 Oct;343(1):134-44
- 49) Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines.
Papageorgiou I, Grepper S, Unadkat JD.
Drug Metab Dispos. 2013 Feb;41(2):281-90.
- 50) Phase 1 and Phase 2 Drug Metabolism and Bile Acid Production of HepaRG Cells in a Bioartificial Liver in Absence of Dimethyl Sulfoxide.
Hoekstra R, Nibourg GA, van der Hoeven TV, Plomer G, Seppen J, Ackermans MT, Camus S, Kulik W, van Gulik TM, Elferink RP, Chamuleau RA.
Drug Metab Dispos. 2013 Mar;41(3):562-7.
- 51) Highly efficient SiRNA and gene transfer into hepatocyte-like HepaRG cells and primary human hepatocytes: new means for drug metabolism and toxicity studies.
Laurent V, Glaize D, Nübel T, Gilot D, Corlu A, Loyer P.
Methods Mol Biol. 2013;987:295-314. doi: 10.1007/978-1-62703-321-3_25.

- 52) Evaluation of Normalization Strategies Used in Real-Time Quantitative PCR Experiments in HepaRG Cell Line Studies.
Ceelen L, De Craene J, De Spiegelaere W.
Clin Chem. 2013 Sep 11.
- 53) Human Placental Lactogen Induces CYP2E1 Expression Via PI 3-kinase Pathway in Female Human Hepatocytes.
Lee JK, Chung HJ, Fischer L, Fischer J, Gonzalez FJ, Jeong H.
Drug Metab Dispos. 2014 Jan 10.
- 54) Thalidomide Increases Human Hepatic Cytochrome P450 3A Enzymes by Direct Activation of the Pregnane X Receptor
Murayama N¹, van Beuningen R, Suemizu H, Guguen-Guillouzo C, Shibata N, Yajima K, Utoh M, Shimizu M, Chesné C, Nakamura M, Guengerich FP, Houtman R, Yamazaki H.
Chem Res Toxicol. 2014 Feb 17;27(2):304-8
- 55) Evaluation of 23 Lots of Commercially Available Cryopreserved Hepatocytes for Induction Assays of Human Cytochromes P450.
Yajima K¹, Uno Y, Murayama N, Uehara S, Shimizu M, Nakamura C, Iwasaki K, Utoh M, Yamazaki H.
Drug Metab Dispos. 2014 Feb 19.
- 56) Comparative study of the effects of anti-tuberculosis drugs and antiretroviral drugs on CYP3A4 and P-glycoprotein.
Horita Y, Doi N.
Antimicrob Agents Chemother. 2014 Mar 24
- 57) Differentiation of liver progenitor cell line to functional organotypic cultures in 3D nanofibrillar cellulose and hyaluronan-gelatin hydrogels.
Malinen MM, Kanninen LK, Corlu A, Isoniemi HM, Lou YR, Yliperttula ML, Urtti AO.
Biomaterials. 2014 Jun;35(19):5110-21.
- 58) Interactions of Endosulfan and Methoxychlor Involving CYP3A4 and CYP2B6 in Human HepaRG_Cells.
Savary CC, Josse R, Guillet F, Bruyere A, Robin MA, Guillouzo A.
Drug Metab Dispos. 2014 May 15. pii: dmd.114.057786
- 59) HepaRG cell line as an in vitro model for screening drug-drug interactions mediated by metabolic induction: Amiodarone used as a model substance.
Ferreira A, Rodrigues M, Silvestre S, Falcão A, Alves G.
Toxicol In Vitro. 2014 Aug 27. pii: S0887-2333(14)00157-X
- 60) Dual-Color Fluorescence Imaging to Monitor CYP3A4 and CYP3A7 Expression in Human Hepatic Carcinoma HepG2 and **HepaRG** Cells.
Tsuji S, Kawamura F, Kubiura M, Hayashi A, Ohbayashi T, Kazuki Y, Chesné C, Oshimura M, Tada M.
PLoS One. 2014 Aug 7;9(8):e104123.
- 61) HepaRG Cells as Human-Relevant In Vitro Model to Study the Effects of Inflammatory Stimuli on Cytochrome P450 Isoenzymes.
Rubin K, Janefeldt A, Andersson L, Berke Z, Grime K, Andersson TB.
Drug Metab Dispos. 2015 Jan;43(1):119-25
- 62) Modulation of Cytochrome P450 expression and induction in human hepatocytes by Wnt/ β -Catenin signaling.
M.Thomas, U.Hofmann, C.Bayha, S.Winter, U.M.Zanger, M.Schwarz, A.Braeuning
20th International Symposium on Microsomes and Drug Oxidations(MDO), 2014 **Poster**
- 63) In vitro-to-in vivo correlation of the skin penetration, liver clearance and hepatotoxicity of caffeine.
Gajewska M, Paini A, Sala Benito JV, Burton J, Worth A, Urani C, Briesen H, Schramm KW.
Food Chem Toxicol. 2015 Jan;75:39-49.

- 64) A systematic comparison of the impact of inflammatory signaling on absorption, distribution, metabolism, and excretion gene expression and activity in primary human hepatocytes and **HepaRG** cells.
Klein M, Thomas M, Hofmann U, Seehofer D, Damm G, Zanger UM.
Drug Metab Dispos. 2015 Feb;43(2):273-83.
- 65) In vitro kinetics of amiodarone and its major metabolite in two human liver cell models after acute and repeated treatments.
Pomponio G, Savary CC, Parmentier C, Bois F, Guillouzo A, Romanelli L, Richert L, Di Consiglio E, Testai E.
Toxicol In Vitro. 2014 Dec 26. pii: S0887-2333(14)00252-5
- 66) Transcriptomic analysis of untreated and drug-treated differentiated **HepaRG** cells over a 2-week period.
Savary CC, Jiang X, Aubry M, Jossé R, Kopp-Schneider A, Hewitt P, Guillouzo A.
Toxicol In Vitro. 2015 Jan 5. pii: S0887-2333(14)00268-9.
- 67) Understanding the biokinetics of ibuprofen after single and repeated treatments in rat and human in vitro liver cell systems.
Truisi GL, Consiglio ED, Parmentier C, Savary CC, Pomponio G, Bois F, Lauer B, Jossé R, Hewitt PG, Mueller SO, Richert L, Guillouzo A, Testai E.
Toxicol Lett. 2015 Jan 8;233(2):172-186. doi: 10.1016
- 68) Detection of main metabolites of XLR-11 and its thermal degradation product in human hepatoma **HepaRG** cells and human urine.
Kanamori T, Kanda K, Yamamuro T, Kuwayama K, Tsujikawa K, Iwata YT, Inoue H.
Drug Test Anal. 2015 Jan 19
- 69) Human **HepaRG** Cells can be Cultured in Hanging-Drop Plates for Cytochrome P450 Induction and Function Assays.
Murayama N, Usui T, Slawny N, Chesné C, Yamazaki H.
Drug Metab Lett. 2015 Jan 18
- 70) Evaluation of differentiated cryopreserved HepaRG cells as a model for hepatic clearance and UGT activity.
Malin Darnell and Tommy B Andersson
Rennes Workshop 2011 **Poster**
- 71) Measuring CYP3A induction in combination with cell viability in multiplex cell-based assays formats. James J. Cali, Marie Sobol, James Unch, Timothy Moeller, Brad Larson and David Steen
ISSX 2010 **Poster**
- 72) Evaluation of the impact of matrix stiffness on encapsulated HepaRG spheroids.
S. P Rebelo, M. Estrada, R. Costa, C. Chesné, C. Brito and P. M Alves
ESACT 2013 **Poster**
- 73) A trial proteomics fingerprint analysis of **HepaRG** cells by FD-LC-MS/MS.
Nakata K, Ichibangase T, Saitoh R, Ishigai M, Imai K.
Analyst. 2015 Jan 7;140(1):71-3
- 74) Activating and Inhibitory Functions of WNT/ β -Catenin in the Induction of Cytochromes P450 by Nuclear Receptors in **HepaRG** Cells.
Thomas M, Bayha C, Vetter S, Hofmann U, Schwarz M, Zanger UM, Braeuning A.
Mol Pharmacol. 2015 Jun;87(6):1013-20.
- 75) Three-dimensional (3D) spheroid cultures improve the metabolic gene expression profiles of HepaRG cells.
Takahashi Y, Hori Y, Yamamoto T, Urashima T, Ohara Y, Tanaka H.
Biosci Rep. 2015 May 7; 35(3) pii:e00208

- 76) Drug biokinetic and toxicity assessments in rat and human primary hepatocytes and_HepaRG_cells within the EU-funded Predict-IV project.
Mueller SO, Guillouzo A, Hewitt PG, Richert L.
Toxicol In Vitro. 2015 May 4. pii: S0887-2333(15)00085-5.
- 77) A ready-to-use, versatile, multiplex-able three-dimensional scaffold-based immunoassay chip for high throughput hepatotoxicity evaluation.
Yan X, Wang J, Zhu L, Lowrey JJ, Zhang Y, Hou W, Dong J, Du Y.
Lab Chip. 2015 Jun 1;15(12):2634-46.
- 78) Two persistent organic pollutants which act through different xenosensors (alpha-endosulfan and 2,3,7,8 tetrachlorodibenzo-p-dioxin) interact in a mixture and downregulate multiple genes involved in human hepatocyte lipid and glucose metabolism.
Ambolet-Camoit A, Ottolenghi C, Leblanc A, Kim MJ, Letourneur F, Jacques S, Cagnard N, Guguen-Guillouzo C, Barouki R, Aggerbeck M.
Biochimie. 2015 Sep;116:79-91.
- 79) Formation of GSH-trapped reactive metabolites in human liver microsomes, S9 fraction, **HepaRG**-cells, and human hepatocytes.
Lassila T, Rousu T, Mattila S, Chesné C, Pelkonen O, Turpeinen M, Tolonen A.
J Pharm Biomed Anal. 2015 Nov 10;115:345-51.
- 80) Measurement of Cytochrome P450 Enzyme Induction and Inhibition in Human Hepatoma Cells.
Rodrigues RM, De Kock J, Doktorova TY, Rogiers V, Vanhaecke T.
Methods Mol Biol. 2015;1250:279-85.
- 81) Human hepatoma cell lines on gas foaming templated alginate scaffolds for in vitro drug-drug interaction and metabolism studies.
Stampella A, Rizzitelli G, Donati F, Mazzarino M, de la Torre X, Botrè F, Giardi MF, Dentini M, Barbetta A, Massimi M.
Toxicol In Vitro. 2015 Oct 9. pii: S0887-2333(15)00253-2.
- 82) Peroxisome proliferator-activated receptor alpha, PPAR α , directly regulates transcription of cytochrome P450 CYP2C8.
Thomas M, Winter S, Klumpp B, Turpeinen M, Klein K, Schwab M, Zanger UM.
Front Pharmacol. 2015 Nov 4;6:261.
- 83) In vitro metabolism of the cyanotoxin cylindrospermopsin in HepaRG cells and liver tissue fractions.
Kittler K, Hurtaud-Pessel D, Maul R, Kolrep F, Fessard V.
Toxicol. 2016 Feb;110:47-50.
- 84) Effects of Hypericum perforatum extract and its main bioactive compounds on the cytotoxicity and expression of CYP1A2 and CYP2D6 in hepatic cells.
Silva SM, Martinho A, Moreno I, Silvestre S, Granadeiro LB, Alves G, Duarte AP, Domingues F, Gallardo E.
Life Sci. 2016 Jan 1;144:30-6.
- 85) Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and_HepaRGcells.
Sugiyama I, Murayama N, Kuroki A, Kota J, Iwano S, Yamazaki H, Hirota T.
Xenobiotica. 2015 Dec 29:1-10.
- 86) Functional polymer-dependent 3D culture accelerates the differentiation of HepaRGcells into mature hepatocytes.
Higuchi Y, Kawai K, Kanaki T, Yamazaki H, Chesné C, Guguen-Guillouzo C, Suemizu H.
Hepatol Res. 2016 Jan 2. doi: 10.1111/hepr.12644.

- 86) Determination of Human Hepatocyte Intrinsic Clearance for Slowly Metabolized Compounds: Comparison of a Primary Hepatocyte/Stromal Cell Co-culture with Plated Primary Hepatocytes and **HepaRG**.
Bonn B, Svanberg P, Janefeldt A, Hultman Ia, Grime K.
Drug Metab Dispos. 2016 Apr;44(4):527-33.
- 87) Mathematical and Experimental Model of Oxygen Diffusion for **HepaRG** Cell Spheroids.
Aleksandrova AV, Pulkova NP, Gerasimenko TN, Anisimov NY, Tonevitskaya SA, Sakharov DA.
Bull Exp Biol Med. 2016 Apr;160(6):857-60.
- 88) A Rapid and Sensitive HPLC-DAD Assay to Quantify Lamotrigine, Phenytoin and Its Main Metabolite in Samples of Cultured HepaRG Cells.
Ferreira A, Rodrigues M, Falcão A, Alves G.
J Chromatogr Sci. 2016 May 18.
- 89) Maintenance of High Cytochrome P450 Expression in **HepaRG** Cell Spheroids in DMSO-Free Medium.
Aleksandrova AV, Burmistrova OA, Fomicheva KA, Sakharov DA.
Bull Exp Biol Med. 2016 May;161(1):120-4.
- 90) Contextualizing Hepatocyte Functionality of Cryopreserved **HepaRG**® Cell Cultures.
Jackson JP, Li L, Chamberlain ED, Wang H, Ferguson SS.
Drug Metab Dispos. 2016 Jun 23.
- NEW!!** 91) Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches.
Richter LH, Kaminski YR, Noor F, Meyer MR, Maurer HH.
Anal Bioanal Chem. 2016 Sep;408(23):6283-94.
- NEW!!** 92) Effect of Circulation Parameters on Functional Status of **HepaRG** Spheroids Cultured in Microbioreactor.
Semenova OV, Petrov VA, Gerasimenko TN, Aleksandrova AV, Burmistrova OA, Khutornenko AA, Osipyants AI, Poloznikov AA, Sakharov DA.
Bull Exp Biol Med. 2016 Jul;161(3):425-9.
- NEW!!** 93) New screening criteria setting on evaluation of cytochrome P450 induction using **HepaRG** cells with multiplex branched DNA technologies in early drug discovery.
Ogasawara A, Yamada Y, Torimoto N, Tsuda N, Aohara F, Ohashi R, Taniguchi H.
Drug Metab Lett. 2016 Aug 22.

Humanized-Liver mouse

- 1) Human hepatoma HepaRG cell line engraftment in severe combined immunodeficient × beige mice using mouse-specific anti-Fas antibody.
Jiang L, Li JG, Lan L, Wang YM, Mao Q, You JP.
Transplant Proc. 2010 Nov;42(9):3773-3778.
- 2) The human hepatic cell line **HepaRG** as a possible cell source for the generation of humanized liver TK-NOG mice.
Higuchi Y, Kawai K, Yamazaki H, Nakamura M, Bree F, Guguen-Guillouzo C, Suemizu H.
Xenobiotica. 2014;44(2):146-153

Drug Transporters

- 1) Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo.
Barraud L, Merle P, Soma E, Lefrançois L, Guerret S, Chevallier M, Dubernet C, Couvreur P, Trépo C, Vitvitski L.
J Hepatol. 2005 May;42(5):736-743.
- 2) Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line.
Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O.
Eur J Pharm Sci. 2006 May;28(1-2):109-117.

- 3) Mechanisms of human hepatobiliary transporter gene regulation in the hepatocyte-like cell line HepaRG.
I.V. Martin, S. Voigt, S. Strauch, C. Trautwein, A. Geier.
Euro Tox.2007 **Poster**
- 4) Long-term cell culture models for the analysis of hepatotoxicity in vitro.
G. Tusch, J. hrach, L. Richert, C. Chesne, P.G. Hewitt, S.O. Mueller.
Eurotox, 2007 **Poster**
- 5) Down-regulation of organic anion transporter expression in human hepatocytes exposed to the pro-inflammatory cytokine interleukin 1 β
Le Vee M, Gripon P, Stieger B, Fardel O.
Drug Metab Dispos 2008 Feb;36(2):217-222.
- 6) Expression of the hepatic efflux transporters MRP1, MRP2, MRP3 and MDR1 in 3D bioreactor cultures of human liver cells.
Bohmer N, Darnell M, Ringel F, Schreiter T, Zeilinger K, Andersson T, Gerlach J.C
ESTIV08 meeting. 2008. **Poster**
- 7) Influx and efflux drug transporters in the human HepaRG hepatocytes.
Trancard MM, Camus S, Rougier N, Li R, Chesne C.
Biomedical Ttransporters. 2009. **Poster**
- 8) Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters.
Picard N, Levoir L, Lamoureux F, Yee SW, Giacomini KM, Marquet P.
Xenobiotica. 2011 Sep; 41(9): 752-757.
- 9) Evaluation of Organic Anion-Transporting Polypeptide 1B1 and CYP3A4 Activities in Primary Human Hepatocytes and HepaRG Cells Cultured in a Dynamic Three-Dimensional Bioreactor System.
Ulvestad M, Darnell M, Molden E, Ellis E, Asberg A, Andersson TB.
J Pharmacol Exp Ther. 2012 Oct;343(1):145-56
- 10) Expression and Transport Function of Drug Uptake Transporters in Differentiated HepaRG Cells.
Kotani N, Maeda K, Debori Y, Camus S, Li R, Chesne C, Sugiyama Y.
Mol Pharm. 2012 Nov 6.
- 11) Differential regulation of drug transporter expression by all-trans retinoic acid in hepatoma HepaRG cells and human hepatocytes.
Le Vee M, Jouan E, Stieger B, Fardel O.
Eur J Pharm Sci. 2013 Mar 12;48(4-5):767-74.
- 12) Comparative distribution and function of canalicular and basolateral transporters in HepaRG[®] cells, HepG2 cells and primary human hepatocytes
P.Bachour-El Azzi, R.Li, A. Charanek, Z.Abedel-Rezzak, C.Guguen-Guillouzo, A.Guillouzo and C.Chesne.
SOT's 52nd Annual Meeting, 2013. Mar. **Poster**
- 13) Comparison of human hepatoma HepaRG cells with human and rat hepatocytes in uptake transport assays in order to predict a risk of drug induced hepatotoxicity.
Szabo M, Veres Z, Baranyai Z, Jakab F, Jemnitz K.
PLoS One. 2013;8(3):e59432..
- 14) Polarized expression of drug transporters in differentiated human hepatoma HepaRG cells.
Le Vee M, Noel G, Jouan E, Stieger B, Fardel O.
Toxicol In Vitro. 2013 Jul 12;27(6):1979-1986.
- 15) Regulation of Hepatic Drug Transporter Activity and Expression by Organochlorine Pesticides.
Bucher S, Le Vee M, Jouan E, Fardel O.
J Biochem Mol Toxicol. 2013 Nov 27.
- 16) Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes.
Bachour-El Azzi P, Sharanek A, Burban A, Li R, Guével RL, Abdel-Razzak Z, Stieger B, Guguen-Guillouzo C, Guillouzo A.
Toxicol Sci. 2015 May;145(1):157-68. doi: 10.1093/toxsci/kfv041. Epub 2015 Feb 17.

- 17) Protein kinase C-dependent regulation of human hepatic drug transporter expression.
Mayati A, Le Vee M, Moreau A, Jouan E, Bucher S, Stieger B, Denizot C, Parmentier Y, Fardel O.
Biochem Pharmacol. 2015 Oct 14. pii: S0006-2952(15)00661-9.
- 18) The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by sequestrating SRC-1 coactivator.
Hyrsova L, Smutny T, Carazo A, Moravcik S, Mandikova J, Trejtnar F, Gerbal-Chaloin S, Pavek P.
Br J Pharmacol. 2016 Feb 27. doi: 10.1111/bph.13472.
- NEW!!** 19) Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate.
Sayyed K, Vee ML, Abdel-Razzak Z, Jouan E, Stieger B, Denizot C, Parmentier Y, Fardel O.
Toxicology. 2016 Jul 1;363-364:58-71.

Genotoxicity , toxicity

- 1) The human hepatoma HepaRG cells: A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.
Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C.
Chem Biol Interact 2007 May; 168(1):66-73.
- 2) How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM workshop.
Kikland D, Pfuhler S, Tweats D, Aardema M, Corvi R, Darroudi F, Elhajouji A, Glatt H, Hastwell P, Hayashi M, Kasper P, Kirchner S, Lynch A, Marzin D, Maurici D, Meunier JR, Muller L, Nohynek G, Parry J, Parry E, Thybaud V, Tice R, van Benthem J, Vanparys P, White P.
Mutat Res 2007 Mar ;628(1):31-55
- 3) Phenobarbital effects on gene expression in human HepaRG cells.
Clambert C., Spire C., Renaud M-P., Platel A., Guillouzo A., Claude N.
SOT meeting 2007. **Poster**
- 4) Human hepatoma HepaRG cells : a unique model system for xenobiotic metabolism and toxicity studies.
Corlu A., Aninat C., Josse R., Glaise D., Morel F., Guillouzo A., Guguen-Guillouzo C.,
IUTOX meeting 2008. **Poster**
- 5) Evolving concepts in liver tissue modeling and implications for in vitro toxicology.
Guillouzo A. and Guguen-Guillouzo C.
Expert Opin. Drug. Metab. Toxicol. 2008; 4(10): 1279-1294. Review.
- 6) Long-Term Functional Stability of Human HepaRG Hepatocytes and Use for Chronic Toxicity and Genotoxicity Studies.
Josse R, Anninat C, Glaise D, Dumont J, Fessard V, Morel F, Poul JM, Guguen-Guillouzo C, Guillouzo A.
Drug, Metab, Dispos. 2008 Jun; 36 (6) : 1111-1118.
- 7) Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes.
Petit E, Langouet S, Akhdar H, Nicolas-Nicolaz C, Guillouzo A, Morel F.
Toxicol. In Vitro. 2008 Apr ; 22(3): 632-642
- 8) The human hepatoma HepaRG cells: a suitable in vitro model to assess the genotoxic potential of bioactivated chemicals by the comet and the cytokinesis-block micronucleus assays.
Ludovic Le Hégarat, Sylvie Huet, Rachelle Lancelot, Annick mourot, Valerie Fessard, Jean-Michel Poul, Rozenn Josse.
EUROPEAN ENVIRONMENTAL MUTAGEN SOCIETY, 38th Annual Meeting,
ENVIRONMENTAL MUTAGENS AND HUMAN HEALTH September. 2008. **Poster**
- 9) New perspectives in the use of human hepatocytes in the preclinical drug development process.
Guillouzo A.
Ann Pharm. Fr. 2008 Nov-Dec ; 66(5-6): 288-295 (in French)

- 10) Comparison of HepG2 and HepaRG cell lines exposed to different carcinogens by gene expression analyses.
D.G.J Jennen, C.Magkoufopoulou, H.B.Ketelslegers, M.H.M van Herwijnen, J.C.S.Kleinjans, J.H.M van Delft
SOT meeting.2009. in Baltimore. **Poster**
- 11) Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions.
Lambert C. B., Spire C., Renaud MP., Claude N., Guillouzo A.
Toxicol. In Vitro. 2009 Apr; 23(3): 466-475.
- 12) Stem cell-derived hepatocytes and their use in toxicology.
Guguen-Guillouzo C, Corlu A, Guillouzo A.
Toxicology. 2010 Mar; 270(1): 3-9
- 13) Genotoxicity of a freshwater cyanotoxin, cylindrospermopsin, in two human cell lines: Caco-2 and HepaRG.
Bazin E, Mourot A, Humpage AR, Fessard V.
Environ Mol Mutagen. 2010 Apr ; 51(3) : 251-259.
- 14) Comparison of HepG2 and HepaRG by whole genome gene expression analysis for the purpose of chemical hazard identification.
Jennen DG, Magkoufopoulou C, Ketelslegers HB, van Herwijnen MH, Kleinjans JC, van Delft JH.
Toxicol Sci. 2010 May; 115(1): 66-79.
- 15) Acetaminophen-induced injury in HepaRG cells: a novel human cell line for studies of drug hepatotoxicity.
Mitchell R. McGill, huimin Yan, Anup Ramachandran, and Hartmut Jaeschke.
SOT meeting 2010. **Poster**
- 16) Differential toxicity of heterocyclic aromatic amines and their mixture in metabolically competent HepaRG cells.
Dumont J., Josse R., Lambert C., Antherieu S., Le Hegarat L. , Aninat C., Robin MA., Guguen-Guillouzo C., Guillouzo A.
Toxicol. Appl. Pharmacol. 2010 Jun; 245(2): 256-263.
- 17) Enrichment of hepatocytes in a HepaRG culture using spatially selective photodynamic treatment.
Bednarkiewicz A, Rodrigues RM, Whelan MP.
J Biomed Opt. 2010 Mar-Apr;15(2):028002.
- 18) Assessment of the genotoxic potential of indirect chemical mutagens in HepaRG cells by the comet and the cytokinesis-block micronucleus assays.
Le Hegarat L, Dumont J, Josse R, Huet S, Lancelleur R, Mourot A, Poul JM, Guguen-Guillouzo C, Guillouzo A, Fessard V.
Mutagenesis. 2010 Nov; 25(6): 555-560.
- 19) Highly efficient gene transfer into hepatocyte-like HepaRG cells: new means for drug metabolism and toxicity studies.
Laurent V, Fraix A, Montier T, Cammas-Marion S, Ribault C, Benvegna T, Jaffres PA, Loyer P.
Biotechnol J. 2010 Mar;5(3):314-320
- 20) The application of 3D micropatterning of agarose substrate for cell culture and in situ comet assays.
Mercey E, Obeid P, Glaise D, Calvo-Muñoz ML, Guguen-Guillouzo C, Fouqué B.
Biomaterials. 2010 Apr;31(12):3156-3165
- 21) Preferential induction of the AhR gene battery in HepaRG cells after a single or repeated exposure to heterocyclic aromatic amines.
Dumont J, Jossé R, Lambert C, Anthérieu S, Laurent V, Loyer P, Robin MA, Guillouzo A.
Toxicol Appl Pharmacol. 2010 Nov 15;249(1):91-100.
- 22) Acetaminophen Hepatotoxicity: Mechanistic Investigations with HepaRG cells.
Hartmut Jaeschke.
SOT meeting 2011. **Oral Presentation**
- 23) Integration of HepaRG cells from Biopredic with Promega's ADME-Tox technologies.
James Cali, Mary Sobol, John Shultz, Jolanta Vidugiriene.
SOT meeting 2011. **Oral Presentation**

- 24) Measuring Mitochondrial Dysfunction in HepaRG Cells.
James Hynes
SOT meeting 2011. **Oral Presentation**
- 25) HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity.
McGill MR, Yan HM, Ramachandran A, Murray GJ, Rollins DE, Jaeschke H.
Hepatology. 2011 Mar;53(3):974-982.
→ 参照: 22) Acetaminophen Hepatotoxicity: Mechanistic Investigations with HepaRG cells.
- 26) In Vitro Genotoxicity Test Approaches with Better Predictivity: Summary of an IWGT Workshop.
Pfuhler S, Fellows M, van Benthem J, Corvi R, Curren R, Dearfield K, Fowler P, Frötschl R, Elhajouji A, Le Hégarat L, Kasamatsu T, Kojima H, Ouédraogo G, Scott A, Speit G.
Mutat Res. 2011 Aug; 723(2): 101-107.
- 27) Automated detection of hepatotoxic compounds in human hepatocytes using HepaRG cells and image-based analysis of mitochondrial dysfunction with JC-1 dye.
Pernelle K, Le Guevel R, Glaise D, Stasio CG, Le Charpentier T, Bouaita B, Corlu A, Guguen-Guillouzo C.
Toxicol Appl Pharmacol. 2011 Aug 1;254(3):256-266.
- 28) Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes.
Limonciel A, Aschauer L, Wilmes A, Prajczek S, Leonard MO, Pfaller W, Jennings P.
Toxicol In Vitro. 2011 Dec; 25(8): 1855-1862.
- 29) An adaptation of the human HepaRG cells to the *in vitro* micronucleus assay
Rozenn Jossé, Alexandra Rogue, Elisabeth Lorge, and André Guillouzo
Mutagenesis .2012 May; 27(3): 295-304.
- 30) Developing a screening system for hepatotoxicity by combining the HepaRG cell model with high content imaging.
Milena Mennecozzi, Maria Tsaneva, Luis Saavedra, Roman Liska, Maurice Whelan. 2011. SOT meeting.
- 31) Identification of early target genes of aflatoxin B1 in human hepatocytes, inter-individual variability and comparison with other genotoxic compound.
Rozenn Josse, Julie Dumont, Alain Fautrel, Marie-Anne Robin, Andre Guillozo.
Toxicol. Appl. Pharmacol. 2012 Jan; 258(2) : 176-187.
- 32) Interactions between hepatitis B virus and aflatoxin B1: effect on p53 induction in HepaRG cells.
Myriam Lereau, Doriane Gouas, Stéphanie Villar, Ahmad Besaratinia, Agnès Hautefeuille, Pascale Berthillon, Ghislaine Martel-Planche, André Nogueira da Costa, Sandra Ortiz-Cuaran, Olivier Hantz, Gerd P. Pfeifer, Pierre Hainaut, Isabelle Chemin.
JGV 2012 Mar; 93(Pt3): 640-650.
- 33) Pre-validation study using the human hepatoma HepaRG cells for detecting genotoxic compounds with the cytokinesis-micronucleus assay.
L. Le Hegarat, A. mourot, S. Huet, L. Vasseur, S. Camus, N. Rougier, C. Chesne V. Fessard
ISSX Meeting 2012. **Poster**
- 34) 3D HepaRG Model as an attractive tool for toxicity testing.
Leite SB, Wilk-Zasadna I, Zaldivar Comenges JM, Airola E, Reis-Fernandes MA, Mennecozzi M, Guguen-Guillouzo C, Chesne C, Gouillou C, Alves PM, Coecke S.
Toxicol Sci. 2012 Jul 27
- 35) Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co-culture biochip.
Choucha-Snouber L, Aninat C, Grsicom L, Madalinski G, Brochot C, Poleni PE, Razan F, Guillouzo CG, Legallais C, Corlu A, Leclerc E.
Biotechnol Bioeng. 2012
- 36) Modulation of ethanol effect on hepatocyte proliferation by polyamines.
Do TH, Gaboriau F, Morel I, Lepage S, Cannie I, Loréal O, Lescoat G.
Amino Acids. 2012 Oct 11.
- 37) Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells.
Anthérieu S, Azzi PB, Dumont J, Abdel-Razzak Z, Guguen-Guillouzo C, Fromenty B, Robin MA, Guillouzo A.
Hepatology. 2012 Nov 23.doi: 10.1002/hep.26160

- 38) Assessment of an automated in vitro basal cytotoxicity test system based on metabolically-competent cells.
Rodrigues RM, Bouhifd M, Bories G, Sacco MG, Gribaldo L, Fabbri M, Coecke S, Whelan MP.
Toxicol In Vitro. 2013 Mar;27(2):760-7.
- 39) In vitro biokinetics of chlorpromazine and the influence of different dose metrics on effect concentrations for cytotoxicity in Balb/c 3T3, Caco-2 and HepaRG cell cultures.
Broeders JJ, Blaauboer BJ, Hermens JL.
Toxicol In Vitro. 2013 Jan 30;27(3):1057-1064.
- 40) 3D Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity Studies.
Gunness P, Mueller D, Shevchenko V, Heinzle E, Ingelman-Sundberg M, Noor F.
Toxicol Sci. 2013 Mar 6.
- 41) Transcriptomic responses generated by hepatocarcinogens in a battery of liver-based in vitro models.
Doktorova TY, Yildirimman R, Vinken M, Vilardell M, Vanhaecke T, Gmuender H, Bort R, Brolen G, Holmgren G, Li R, Chesne C, van Delft J, Kleinjans J, Castell J, Bjorquist P, Herwig R, Rogiers V.
Carcinogenesis. 2013 Mar 8.
- 42) 3D organotypic cultures of human hepaRG cells: a tool for *in vitro* toxicity studies.
Patrina Gunness, Daniel Mueller, Valey Shevchenko, Elmar Heinzle, Magnus Ingelman-Sundberg, Fozia Noor,
SOT's 52nd Annual Meeting, 2013. Mar. **Poster**
- 43) Metabolic characterization of cell systems used in in vitro toxicology testing: Lung cell system BEAS-2B as a working example.
Garcia-Canton C, Minet E, Anadon A, Meredith C.
Toxicol In Vitro. 2013 May 10;27(6):1719-1727.
- 44) Cyclosporine A treated in vitro models induce cholestasis response through comparison of phenotype-directed gene expression analysis of in vivo Cyclosporine A-induced cholestasis.
Kienhuis AS, Vitins AP, Pennings JL, Pronk TE, Speksnijder EN, Roodbergen M, van Delft JH, Luijten M, van der Ven LT.
Toxicol Lett. 2013 Aug 29;221(3):225-36.
- 45) 3D organotypic **HepaRG** cultures as in vitro model for acute and repeated dose toxicity studies.
Mueller D, Krämer L, Hoffmann E, Klein S, Noor F.
Toxicol In Vitro. 2013 Jul 9.
- 46) Baseline and genotoxic compound induced gene expression profiles in HepG2 and **HepaRG** compared to primary human hepatocytes.
Jetten MJ, Kleinjans JC, Claessen SM, Chesné C, van Delft JH.
Toxicol In Vitro. 2013 Jul 31. Article in Press
- 47) Iron-mediated effect of alcohol on hepatocyte differentiation in **HepaRG** cells.
Do TH, Gaboriau F, Cannie I, Batusanski F, Ropert M, Moirand R, Brissot P, Loreal O, Lescoat G.
Chem Biol Interact. 2013 Sep 8. doi:pii: S0009-2797(13)
- 48) Long-term maintenance of **HepaRG** cells in serum-free conditions and application in a repeated dose study.
Klein S, Mueller D, Schevchenko V, Noor F.
J Appl Toxicol. 2013 Sep 30. doi: 10.1002/jat.2929
- 49) Studies on the Role of Metabolic Activation in Tyrosine Kinase Inhibitor (TKI)-dependent Hepatotoxicity: Induction of CYP3A4 Enhances the Cytotoxicity of Lapatinib in HepaRG Cells.
Hardy KD, Wahlin MD, Papageorgiou I, Unadkat J, Rettie AE, Nelson SD.
Drug Metab Dispos. 2013 Nov 15.
- 50) Impact of isomalathion on malathion cytotoxicity and genotoxicity in human HepaRG cells.
Josse R, Sharanek A, Savary CC, Guillouzo A.
Chem Biol Interact. 2013 Dec 12;209C:68-76.

- 51) Cellular impact of combinations of endosulfan, atrazine, and chlorpyrifos on human primary hepatocytes and HepaRG cells after short and chronic exposures.
Nawaz A, Razpotnik A, Rouimi P, de Sousa G, Cravedi JP, Rahmani R.
Cell Biol Toxicol. 2013 Dec 17
- 52) Performance of Comet and Micronucleus Assays in Metabolic Competent **HepaRG** Cells to Predict In Vivo Genotoxicity.
Hégarat LL, Mouroit A, Huet S, Vasseur L, Camus S, Chesné C, Fessard V.
Toxicol Sci. 2014 Feb 3.
- 53) CYP3A4 activity reduces the cytotoxic effects of okadaic acid in **HepaRG** cells.
Kittler K, Fessard V, Maul R, Hurtaud-Pessel D.
Arch Toxicol. 2014 Feb 7.
- 54) Absence of in vitro genotoxicity potential of the mycotoxin deoxynivalenol in bacteria and in human TK6 and HepaRG cell lines.
Takakura N, Nesslany F, Fessard V, Le Hegarat L.
Food Chem Toxicol. 2014 Jan 24. pii: S0278-6915(14)00043-X.
- 55) Different Dose-Dependent Mechanisms Are Involved in Early Cyclosporine A-Induced Cholestatic Effects in HepaRG Cells.
Sharaneek A, Azzi PB, Al-Attrache H, Savary CC, Humbert L, Rainteau D, Guguen-Guillouzo C, Guillouzo A.
Toxicol Sci. 2014 Sep 1;141(1):244-53.
- 56) Detection of dichlorvos adducts in a hepatocyte cell line.
Bui-Nguyen TM, Dennis WE, Jackson DA, Stallings JD, Lewis JA.
J Proteome Res. 2014 Aug 1;13(8):3583-95
- 57) Impact of inflammation on chlorpromazine-induced cytotoxicity and cholestatic features in HepaRG cells.
Bachour-El Azzi P, Sharaneek A, Abdel-Razzak Z, Antherieu S, Al-Attrache H, Savary CC, Lepage S, Morel I, Labbe G, Guguen-Guillouzo C, Guillouzo A.
Drug Metab Dispos. 2014 Sep;42(9):1556-66.
- 58) Antioxidant potential of *Sutherlandia frutescens* and its protective effects against oxidative stress in various cell cultures.
Tobwala S, Fan W, Hines CJ, Folk WR, Ercal N.
BMC Complement Altern Med. 2014 Jul 29;14:271.
- 59) Comparative evaluation of N-acetylcysteine and N-acetylcysteineamide in acetaminophen-induced hepatotoxicity in human hepatoma **HepaRG** cells.
Tobwala S, Khayyat A, Fan W, Ercal N.
Exp Biol Med (Maywood). 2015 Feb;240(2):261-72
- 60) Expression of stress-dependent genes in hepatocytes spheroids after cisplatin treatment.
Rusanov AL, Pul'kova NV, Klonova MG, Fomicheva KA, Kozhin PM, Sevast'yanova MA, Shkurnikov MY.
Bull Exp Biol Med. 2014 Sep;157(5):603-7
- 61) Live spheroid formation recorded with light sheet-based fluorescence microscopy.
Pampaloni F, Richa R, Ansari N, Stelzer EH.
Methods Mol Biol. 2015;1251:43-57
- 62) The role of the c-Jun N-terminal kinases 1/2 and receptor-interacting protein kinase 3 in furosemide-induced liver injury
McGill MR, Du K, Xie Y, Bajt ML, Ding WX, Jaeschke H.
Xenobiotica. 2014 Nov 25:1-8.

- 63) Analysis of Four Hepatotoxicants Using the xCelligence Analytical System and HepaRG Cells.
C.Jin, D.Steen, V.Shevchenko, C.Chesne, Y.Abassi
SOT 2014 **Poster**
- 64) IDENTIFICATION OF DRUG-INDUCED MITOCHONDRIAL ALTERATIONS USING THE HEPARG CELL LINE.
N.Buron, M.Porcededu, C.Pertuiset, D.Steen, S.Camus, C.Chesne, A.B-Sanchez
19th North American ISSX Meeting and 29th JSSX Annual Meeting, 2014. **Poster**
- 65) Biokinetics of chlorpromazine in primary rat and human hepatocytes and human **HepaRG** cells after repeated exposure.
Broeders JJ, Parmentier C, Truissi GL, Jossé R, Alexandre E, Savary CC, Hewitt PG, Mueller SO, Guillouzo A, Richert L, van Eijkeren JC, Hermens JL, Blaauboer BJ.
Toxicol In Vitro. 2014 Nov 4. pii: S0887-2333(14)
- 66) Organocatalysis paradigm revisited: are metal-free catalysts really harmless?
Nachtergaele A, Coulembier O, Dubois P, Helvenstein M, Duez P, Blankert B, Mespouille L.
Biomacromolecules. 2015 Feb 9;16(2):507-14. doi: 10
- 67) HepaRG culture in tethered spheroids as an in vitro three-dimensional model for drug safety screening.
Wang Z, Luo X, Anene-Nzeli C, Yu Y, Hong X, Singh NH, Xia L, Liu S, Yu H.
J Appl Toxicol. 2014 Dec 15.
- 68) New insights in dose-dependent mechanisms involved in cyclosporine A-induced cholestasis in HepaRG™ cells. Comparison with tacrolimus.
A. Sharaneck, P. B.-El Azzi, H. Al-Attrache, C. C. Savary, C.Guguen-Guillouzo and A. Guillouzo,
SOT 2014, **poster**
- 69) Gene expression profiles in HepaRG™ cells to discriminate genotoxic from non genotoxic compounds.
D. Giret, A. Huguet, S.Camus, N. Rougier, C.Chesné, V. Fessard and L. Le Hegarat
EEMS 2012 **Poster**
- 70) Comparison of Different Cell Models in High Content Screening to Investigate Metabolism-Mediated Hepatotoxicity
Walker, P., Fox, K., Butler P., Annand R., Mouchet, N., Camus S.; Dilworth C., Chesne, C., Gill, H.,; Tsaïoun K.,
2011 **Poster**
- 71) Amiodarone-Induced Phospholipidosis And Steatosis In Human Hepatoma HepaRG Cells.
S. Anthérieu, C.Chesné, A. Guillouzo
Lintop Project 2009 **Poster**
- 72) Alterations of the Bile Acid transport system by Cyclosporine A in HepaRG cells.
A.Sharaneck, P.Bachour-El Azzi, C. Guguen-Guillouzo, A. Guillouzo
EUSAAT 2013 **Poster**
- 73) Comparative evaluation of N-acetylcysteine and N-acetylcysteineamide in acetaminophen-induced hepatotoxicity in human hepatoma HepaRG cells.
Tobwala S, Khayyat A, Fan W, Ercal N.
Exp Biol Med (Maywood). 2015 Feb;240(2):261-72.
- 74) High Content Imaging and Analysis Enable Quantitative In Situ Assessment of CYP3A4 Using Cryopreserved Differentiated HepaRG Cells.
Ranade AR, Wilson MS, McClanahan AM, Ball AJ.
J Toxicol. 2014;2014:291054

- 75) In vitro-to-in vivo correlation of the skin penetration, liver clearance and hepatotoxicity of caffeine.
Gajewska M, Paini A, Sala Benito JV, Burton J, Worth A, Urani C, Briesen H, Schramm KW.
Food Chem Toxicol. 2015 Jan;75:39-49. doi: 10.1016/j.fct.2014.10.017. Epub 2014 Nov 4.
- 76) In vitro kinetics of amiodarone and its major metabolite in two human liver cell models after acute and repeated treatments.
Pomponio G, Savary CC, Parmentier C, Bois F, Guillouzo A, Romanelli L, Richert L, Di Consiglio E, Testai E.
Toxicol In Vitro. 2014 Dec 26. pii: S0887-2333(14)00252-5.
- 77) Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondria.
Hu D, Wu CQ, Li ZJ, Liu Y, Fan X, Wang QJ, Ding RG.
Toxicol Appl Pharmacol. 2015 Apr 15;284(2):134-41.
- 78) BK/TD models for analyzing in vitro impedance data on cytotoxicity.
Teng S, Barcellini-Couget S, Beaudouin R, Brochot C, Desousa G, Rahmani R, Pery AR.
Toxicol Lett. 2015 Jun 1;235(2):96-106. doi: 10.1016/j.toxlet.2015.03.011. Epub 2015 Mar 28.
- 79) Hepatotoxicity of piperazine designer drugs: Comparison of different in vitro models.
Dias-da-Silva D, Arbo MD, Valente MJ, Bastos ML, Carmo H.
Toxicol In Vitro. 2015 Aug;29(5):987-96.
- 80) Time course of acetaminophen-protein adducts and acetaminophen metabolites in circulation of overdose patients and in HepaRG cells.
Xie Y, McGill MR, Cook SF, Sharpe MR, Winefield RD, Wilkins DG, Rollins DE, Jaeschke H.
Xenobiotica. 2015 Apr 14:1-9.
- 81) Hepatic TLR4 signaling in obese NAFLD.
Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peek RM Jr, Abumrad NN, Flynn CR.
AM J Physiol Gastrointest Liver Physiol. 2015 Aug 15;309(4):G270-8.
- 82) Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication.
Sison-Young RL, Mitsa D, Jenkins RE, Mottram D, Alexandre E, Richert L, Aerts H, Weaver RJ, Jones RP, Johann E, Hewitt PG, Ingelman-Sundberg M, Goldring CE, Kitteringham NR, Park BK.
Toxicol Sci. 2015 Oct;147(2):412-24.
- 83) Bile Acid-Induced Toxicity in HepaRG Cells Recapitulates the Response in Primary Human Hepatocytes.
Woolbright BL, McGill MR, Yan H, Jaeschke H.
Basic Clin Pharmacol Toxicol. 2015 Jul 14.
- 84) Kinetics and dynamics of cyclosporine A in three hepatic cell culture systems.
Bellwon P, Truisi GL, Bois FY, Wilmes A, Schmidt T, Savary CC, Parmentier C, Hewitt PG, Schmal O, Josse R, Richert L, Guillouzo A, Mueller SO, Jennings P, Testai E, Dekant W.
Toxicol In Vitro. 2015 Jul 17. pii: S0887-2333(15)00177-0.
- 85) Cellular Accumulation and Toxic Effects of Bile Acids in Cyclosporine A-Treated HepaRG Hepatocytes.
Sharanek A, Burban A, Humbert L, Bachour-El Azzi P, Felix-Gomes N, Rainteau D, Guillouzo A.
Toxicol Sci. 2015 Oct;147(2):573-87.
- 86) Evaluation of genotoxicity using automated detection of γ H2AX in metabolically competent HepaRG cells.
Quesnot N, Rondel K, Audebert M, Martinais S, Glaise D, Morel F, Loyer P, Robin MA.
Mutagenesis. 2015 Aug 17. pii: gev059.

- 87) Metabolomics analysis of the toxicity pathways of triphenyl phosphate in **HepaRG** cells and comparison to oxidative stress mechanisms caused by acetaminophen.
Van den Eede N, Cuykx M, Rodrigues RM, Laukens K, Neels H, Covaci A, Vanhaecke T.
Toxicol In Vitro. 2015 Dec;29(8):2045-54.
- 88) Biokinetics in repeated-dosing in vitro drug toxicity studies.
Kramer NI, Di Consiglio E, Blaauboer BJ, Testai E.
Toxicol In Vitro. 2015 Sep 8. pii: S0887-2333(15)00218-0.
- 89) In silico modeling for the prediction of dose and pathway related adverse effects in humans from in vitro repeated-dose studies.
Klein S, Maggioni S, Bucher J, Mueller D, Niklas J, Shevchenko V, Mauch K, Heinzle E, Noor F.
Toxicol Sci. 2015 Sep 29. pii: kfv218.
- 90) Toxicogenomics-based prediction of acetaminophen-induced liver injury using human hepatic cell systems.
Rodrigues RM, Heymans A, De Boe V, Sachinidis A, Chaudhari U, Govaere O, Roskams T, Vanhaecke T, Rogiers V, De Kock J.
Toxicol Lett. 2015 Oct 20;240(1):50-59.
- 91) A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury.
Oda S, Matsuo K, Nakajima A, Yokoi T.
Toxicol Lett. 2015 Nov 4. pii: S0378-4274(15)30094-1. doi: 10.1016/j.toxlet.2015.10.029. [Epub ahead of print]
- 92) Toxicity of Carboxylic Acid-Containing Drugs: The Role of Acyl Migration and CoA Conjugation Investigated.
Lassila T, Hokkanen J, Aatsinki SM, Mattila S, Turpeinen M, Tolonen A.
Chem Res Toxicol. 2015 Dec 21;28(12):2292-303.
- 93) MicroRNA Responses to the Genotoxic Carcinogens Aflatoxin B1 and Benzo[a]pyrene in Human HepaRG Cells.
Marrone AK, Tryndyak V, Beland FA, Pogribny IP.
Toxicol Sci. 2016 Feb;149(2):496-502. doi: 10.1093/toxsci/kfv253. Epub 2015 Nov 24.
- 94) Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro.
Leite SB, Roosens T, El Taghdouini A, Mannaerts I, Smout AJ, Najimi M, Sokal E, Noor F, Chesne C, van Grunsven LA.
Biomaterials. 2016 Feb;78:1-10.
- 95) Lack of Direct Cytotoxicity of Extracellular ATP against Hepatocytes: Role in the Mechanism of Acetaminophen Hepatotoxicity.
Xie Y, Woolbright BL, Kos M, McGill MR, Dorko K, Kumer SC, Schmitt TM, Jaeschke H.
J Clin Transl Res. 2015;1(2):100-106.
- 96) A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen.
Michaut A, Le Guillou D, Moreau C, Bucher S, McGill MR, Martinais S, Gicquel T, Morel I, Robin MA, Jaeschke H, Fromenty B.
Toxicol Appl Pharmacol. 2016 Feb 1;292:40-55.
- 97) Reduced cardiolipin content decreases respiratory chain capacities and increases ATP synthesis yield in the human HepaRG cells.
Peyta L, Jamouen K, Pinault M, Guimaraes C, Pais de Barros JP, Chevalier S, Dumas JF, Maillot F, Hatch GM, Loyer P, Servais S.
Biochim Biophys Acta. 2016 Apr;1857(4):443-53.
- 98) MicroRNA changes, activation of progenitor cells and severity of liver injury in mice induced by choline and folate deficiency.
Tryndyak VP, Marrone AK, Latendresse JR, Muskhelishvili L, Beland FA, Pogribny IP.
J Nutr Biochem. 2016 Feb;28:83-90.

- 99) Establishment of a Drug-Induced, Bile Acid-Dependent Hepatotoxicity Model Using **HepaRG** Cells.
Susukida T, Sekine S, Nozaki M, Tokizono M, Oizumi K, Horie T, Ito K.
J Pharm Sci. 2016 Apr;105(4):1550-60.
- 100) Modulation of CYP3A4 activity alters the cytotoxicity of lipophilic phycotoxins in human hepatic **HepaRG** cells.
Ferron PJ, Hogeveen K, De Sousa G, Rahmani R, Dubreil E, Fessard V, Le Hegarat L.
Toxicol In Vitro. 2016 Jun;33:136-46.
- 101) Engineering EMT using 3D micro-scaffold to promote hepatic functions for drug hepatotoxicity evaluation.
Wang J, Chen F, Liu L, Qi C, Wang B, Yan X, Huang C, Hou W, Zhang MQ, Chen Y, Du Y.
Biomaterials. 2016 Jun;91:11-22.
- 102) Grouping Thirty Four Chemicals Based on Mode of Action Using Connectivity Mapping.
De Abrew KN, Kainkaryam RM, Shan YK, Overmann GJ, Settivari RS, Wang X, Xu J, Adams RL, Tiesman JP, Carney EW, Naciff JM, Daston GP.
Toxicol Sci. 2016 Mar 29. pii: kfw058.
- 103) The **HepaRG** cell line, a superior in vitro model to L-02, HepG2 and hiHeps cell lines for assessing drug-induced liver injury.
Wu Y, Geng XC, Wang JF, Miao YF, Lu YL, Li B.
Cell Biol Toxicol. 2016 Feb;32(1):37-59.
- 104) Novel roles for AhR and ARNT in the regulation of alcohol dehydrogenases in human hepatic cells.
Attignon EA, Leblanc AF, Le-Grand B, Duval C, Aggerbeck M, Rouach H, Blanc EB.
Arch Toxicol. 2016 Apr 8.
- 105) Advantageous use of **HepaRG** cells for the screening and mechanistic study of drug-induced steatosis.
Tolosa L, Gómez-Lechón MJ, Jiménez N, Hervás D, Jover R, Donato MT.
Toxicol Appl Pharmacol. 2016 Jul 1;302:1-9.
- 106) Transport and Toxicity of Silver Nanoparticles in **HepaRG** Cell Spheroids.
Senyavina NV, Gerasimenko TN, Pulkova NV, Maltseva DV.
Bull Exp Biol Med. 2016 Apr;160(6):831-4.
- 107) Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.
Sharaneck A, Burban A, Burbank M, Le Guevel R, Li R, Guillouzo A, Guguen-Guillouzo C.
Sci Rep. 2016 May;6:24709.
- 108) Characterization of hepatotoxicity mechanisms triggered by designer cathinone drugs (β -keto amphetamines).
Valente MJ, Araújo AM, Bastos ML, Fernandes E, Carvalho F, Guedes de Pinho P, Carvalho M.
Toxicol Sci. 2016 Jun 2.
- 109) Complex Approach to Xenobiotics Hepatotoxicity Testing using a Microfluidic System.
Alexandrova AV, Pul'kova NV, Sakharov DA.
Bull Exp Biol Med. 2016 May;161(1):50-3.
- 110) Differential sensitivity of metabolically competent and non-competent **HepaRG** cells to apoptosis induced by diclofenac combined or not with TNF- α .
Al-Attrache H, Sharaneck A, Burban A, Burbank M, Gicquel T, Abdel-Razzak Z, Guguen-Guillouzo C, Morel I, Guillouzo A.
Toxicol Lett. 2016 Jun 13. pii: S0378-4274(16)30148-5

111) The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells.
Nunn AD, Scopigno T, Pediconi N, Levrero M, Hagman H, Kiskis J, Enejder A.
Sci Rep. 2016 Jun 20;6:28025

112) Bisphenol a induces steatosis in **HepaRG** cells using a model of perinatal exposure.
Bucher S, Jalili P, Le Guillou D, Begriche K, Rondel K, Martinais S, Zalko D, Corlu A, Robin MA, Fromenty B.
Environ Toxicol. 2016 Jun 20.

113) Establishment of A Drug-induced, Bile Acid-dependent Hepatotoxicity Model Using HepaRG Cells.
T.Susukida, S.Sekine, M.Noizaki, M.Tokizono, K.Oizumi, T.Horie and K.Ito.
SOT Meeting 2016. **Poster**

114) Evaluation of drug-induced, bile-acids-dependent hepatocyte toxicity in HepaRG cells.
T.Susukida, S.Sekine, M.Noizaki, M.Tokizono, K.Oizumi and K.Ito.
The 1st Workshop for Japan-korea Young Scientists on Pharmaceuticals 2016. **Poster**

NEW!!
115) A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity.
Sison-Young RL, Lauschke VM, Johann E, Alexandre E, Antherieu S, Aerts H, Gerets HH, Labbe G, Hoët D, Dorau M, Schofield CA, Lovatt CA, Holder JC, Stahl SH, Richert L, Kitteringham NR, Jones RP, Elmasry M, Weaver RJ, Hewitt PG, Ingelman-Sundberg M, Goldring CE, Park BK.
Arch Toxicol. 2016 Jun 25.

NEW!!
116) Human arylacetamide deacetylase hydrolyzes ketoconazole to trigger hepatocellular toxicity.
Fukami T, Iida A, Konishi K, Nakajima M.
Biochem Pharmacol. 2016 Sep 15;116:153-61.

NEW!!
117) Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis.
Burbank MG, Burbank A, Sharanek A, Weaver RJ, Guguen-Guillouzo C, Guillouzo A.
Drug Metab Dispos. 2016 Nov;44(11):1780-1793.

NEW!!
118) Optimization, formulation, and characterization of multiflavonoids-loaded flavanosome by bulk or sequential technique.
Karthivashan G, Masarudin MJ, Kura AU, Abas F, Fakurazi S.
Int J Nanomedicine. 2016 Jul 27;11:3417-34.

NEW!!
119) Metformin Protects Against Acetaminophen Hepatotoxicity by Attenuation of Mitochondrial Oxidant Stress and Dysfunction.
Du K, Ramachandran A, Weemhoff JL, Chavan H, Xie Y, Krishnamurthy P, Jaeschke H.
Toxicol Sci. 2016 Aug 25. pii: kfw158.

NEW!!
120) Opsonisation of nanoparticles prepared from poly(β -hydroxybutyrate) and poly(trimethylene carbonate)-b-poly(malic acid) amphiphilic diblock copolymers: Impact on the in vitro cell uptake by primary human macrophages and **HepaRG** hepatoma cells.
Vene E, Barouti G, Jarnouen K, Gicquel T, Rauch C, Ribault C, Guillaume SM, Cammas-Marion S, Loyer P.
Int J Pharm. 2016 Sep 15;513(1-2):438-452.

NEW!!
121) Accessing 3D microtissue metabolism: Lactate and oxygen monitoring in hepatocyte spheroids.
Weltin A, Hammer S, Noor F, Kaminski Y, Kieninger J, Urban GA.
Biosens Bioelectron. 2016 Jul 28;87:941-948.

NEW!!
122) Design, Synthesis, and Cytotoxicity of 5-Fluoro-2-methyl-6-(4-aryl-piperazin-1-yl) Benzoxazoles.
Al-Harthy T, Zoghaib WM, Pflüger M, Schöpel M, Önder K, Reitsammer M, Hundsberger H, Stoll R, Abdel-Jalil R.
Molecules. 2016 Sep 27;21(10). pii: E1290.

Bioartificial Liver

- 1) Liver progenitor cell line HepaRG differentiated in a bioartificial liver effectively supplies liver support to rats with acute liver failure.
Nibourg GA, Chamuleau RA, van der Hoeven TV, Maas MA, Ruiter AF, Lamers WH, Oude Elferink RP, van Gulik TM, Hoekstra R.
PLoS One. 2012;7(6):e38778. Epub 2012 Jun 18.
- 2) Perfusion flow rate substantially contributes to the performance of the HepaRG-AMC-bioartificial liver.
Nibourg GA, Boer JD, van der Hoeven TV, Ackermans MT, van Gulik TM, Chamuleau RA, Hoekstra R.
Biotechnol Bioeng. 2012 Dec;109(12):3182-8.
- 3) The effect of rat acute-liver-failure plasma on HepaRG cells.
Hoekstra R, Nibourg GA, Hoeven TV, Ackermans MT, Hakvoort TB, Gulik TM, Elferink RP, Chamuleau RA.
Int J Artif Organs. 2012 Sep
- 4) Effects of acute-liver-failure-plasma exposure on hepatic functionality of HepaRG-AMC-Bioartificial Liver.
Nibourg GA, Hoekstra R, van der Hoeven TV, Ackermans MT, Hakvoort TB, van Gulik TM, Chamuleau RA.
Liver Int. 2013 Apr;33(4):516-24.
- 5) Increased hepatic functionality of the human hepatoma cell line **HepaRG** cultured in the AMC bioreactor.
Nibourg GA, Hoekstra R, van der Hoeven TV, Ackermans MT, Hakvoort TB, van Gulik TM, Chamuleau RA.
Int J Biochem Cell Biol. 2013 Aug;45(8):1860-8.
- 6) Profiling the Impact of Medium Formulation on Morphology and Functionality of Primary Hepatocytes in vitro.
Nelson LJ, Treskes P, Howie AF, Walker SW, Hayes PC, Plevris JN.
Sci Rep. 2013 Sep 24;3:2735.
- 7) Rapid fabricating technique for multi-layered human hepatic cell sheets by forceful contraction of the fibroblast monolayer.
Sakai Y, Koike M, Hasegawa H, Yamanouchi K, Soyama A, Takatsuki M, Kuroki T, Ohashi K, Okano T, Eguchi S.
PLoS One. 2013 Jul 26;8(7):e70970.
- 8) Bioartificial livers in vitro and in vivo: tailoring biocomponents to the expanding variety of applications.
van Wenum M, Chamuleau RA, van Gulik TM, Siliakus A, Seppen J, Hoekstra R.
Expert Opin Biol Ther. 2014 Dec;14(12):1745-60.
- 9) The multi-organ chip--a microfluidic platform for long-term multi-tissue coculture.
Materne EM, Maschmeyer I, Lorenz AK, Horland R, Schimek KM, Busek M, Sonntag F, Lauster R, Marx U.
J Vis Exp. 2015 Apr 28;(98):e52526.
- NEW!!** 10) Selecting Cells for Bioartificial Liver Devices and the Importance of a 3D Culture Environment: A Functional Comparison between the HepaRG and C3A Cell Lines.
van Wenum M, Adam AA, Hakvoort TB, Hendriks EJ, Shevchenko V, van Gulik TM, Chamuleau RA, Hoekstra R.
Int J Biol Sci. 2016 Jun 24;12(8):964-78. doi: 10.7150/ijbs.15165. eCollection 2016.

Hepatic Progenitor Cells (HPC)

- 1) Origin and characterization of a human bipotent liver progenitor cell line.
Parent R, Marion MJ, Furio L, Trépo C, Petit MA.
Gastroenterology 2004 Apr; 126(4) :1147-1156.
- 2) Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor.
Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, Gripon P, Kremsdorf D, Guguen-Guillouzo C, Corlu A.
Hepatology 2007 Apr; 45(4) :957-967.
- 3) Translational control plays a prominent role in the hepatocytic differentiation of HepaRG liver progenitor cells.
Parent R, Beretta L.
Genome Biol. 2008 Jan 25; 9(1) R19 (R19.1-14).

- 4) Characterization of the double-stranded RNA responses in human liver progenitor cells.
Maire M, Parent R, Morand AL, Alotte C, Trepo C, Durantel D, Petit MA.
Biochem. Biophys Res Commun. 2008 Apr 11; 368(3) : 556-562
- 5) Generation of functional cholangiocyte-like cells from human pluripotent stem cells and HepaRG cells.
Dianat N, Dubois-Pot-Schneider H, Steichen C, Desterke C, Leclerc P, Raveux A, Combettes L, Weber A, Corlu A, Dubart-Kupperschmitt A.
Hepatology. 2014 Apr 9. doi: 10.1002/hep.27165
- 6) Liver X receptor α (LXR α /NR1H3) regulates differentiation of hepatocyte-like cells via reciprocal regulation of HNF4 α
Chen KT, Pernelle K, Tsai YH, Wu YH, Hsieh JY, Liao KH, Guguen-Guillouzo C, Wang HW.
J Hepatol. 2014 Jul 26. pii: S0168-8278(14)00524-8.
- 7) In-vitro Co-culture Model for (Anti-) fibrotic testing.
S.B.Leite, I.Mannaerts, A.E.Taghdouini, C.Chesne,L.A.van Grunsven
European Society of Toxicology In Vitro 2014 International Conferene, 2014 **Poster**
- 8) Hepatic differentiation of human pluripotent stem cells on human liver progenitorHepaRG-derived acellular matrix.
Kanninen LK, Porola P, Niklander J, Malinen MM, Corlu A, Guguen-Guillouzo C, Urtti A, Yliperttula ML, Lou YR.
Exp Cell Res. 2016 Feb 15;341(2):207-17.
- 9) De novo HAPLN1 expression hallmarks Wnt-induced stem cell and fibrogenic networks leading to aggressive human hepatocellular carcinomas.
Mebarki S, Désert R, Sulpice L, Sicard M, Desille M, Canal F, Schneider HD, Bergeat D, Turlin B, Bellaud P, Lavergne E, Le Guével R, Corlu A, Perret C, Coulouarn C, Clément B, Musso O.
Oncotarget. 2016 May 13.

Hepatitis B Virus

- 1) Infection of a human hepatoma cell line by hepatitis B virus.
Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C.
PNAS 2002 Nov; 99(24) :15655-15660
- 2) Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein.
Gripon P, Cannie I, Urban S.
J Virol. 2005 Feb;79(3):1613-1622.
- 3) Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus.
Jaoudé GA, Sureau C.
J Virol. 2005 Aug;79(16):10460-10466.
- 4) Characterization of a hepatitis B and hepatitis delta virus receptor binding site.
Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnölzer M, Urban S.
Hepatology. 2006 Apr;43(4):750-760.
- 5) Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events.
Rabe B, Glebe D, Kann M.
J Virol. 2006 Jun;80(11):5465-5473.
- 6) Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity.
Blanchet M, Sureau C.
J Virol. 2006 Dec;80(24):11935-11945.
- 7) Viral and cellular determinants involved in hepadnaviral entry.
Glebe D, Urban S. World J
World J. Gastroenterol. 2007 Jan ; 13(1):22-38. Review.

- 8) Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans.
Schulze A, Gripon P, Urban S.
Hepatology. 2007 Dec ;46(6):1759-1768
- 9) Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector.
Lucifora J., Durantel D., Belloni L., Barraud L., Villet S., Vincent IE, Margeridon-Thermet S., Hantz O., Kay A., Levrero M., Zoulim F.
J. Gen. Virol. 2008 Aug; 89(pt8): 1819-1828.
- 10) Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells.
Hantz O., Parent R., Durantel D., Gripon P., Guguen-Guillouzo C., Zoulim F.
J. General Virol. 2009 ;90(pt 1):127-135.
- 11) Proteomic Analysis of HepaRG Cells: A Novel Cell line that supports Hepatitis B virus infection.
Narayan R., Gangadharan B., Hantz O., Antrobus R., Garcia A, Dwek RA, Zitzmann N.
J. Proteome Res. 2009 Jan; 8(1) : 118-122.
- 12) Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
Vincent IE, Lucifora J, Durantel D, Hantz O, Chemin I, Zoulim F, Treppe C.
Antivir Ther. 2009 ; 14(1):131-135
- 13) In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.
Villet S, Billioud G, Pichoud C, Lucifora J, Hantz O, Sureau C, Deny P, Zoulim F.
Gastroenterology. 2009 Jan; 136(1): 168-176.
- 14) The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent.
Le Duff Y, Blanchet M, Sureau C.
J. Virol. 2009 Dec; 83(23):12443-12451.
- 15) The First Transmembrane Domain of the Hepatitis B Virus Large Envelope Protein is Crucial for Infectivity.
Lepere-Douard C, Trotard M, Le Seyec J, Gripon P.
J. Virol. 2009 Nov ;83(22) 11819-11829.
- 16) Hepatitis B virus requires intact caveolin-1 function for productive infection in HepaRG cells.
Macovei A, Radulescu C, Lazar C, Petrescu S, Durantel D, Dwek RA, Zitzmann N, Branza-Nichita N.
J Virol. 2010 Jan; 84(1): 243-53.
- 17) Control of hepatitis B virus replication by innate response of HepaRG cells.
Lucifora J, Durantel D, Testoni B, Hantz O, Levrero M, Zoulim F.
Hepatology. 2010 Jan; 51(1); 63-72.
- 18) Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction.
Schulze A, Schieck A, Ni Y, Mier W, Urban S.
J Virol. 2010 Feb;84(4):1989-2000.
- 19) Analysis of the epitope and neutralizing capacity of human monoclonal antibodies induced by hepatitis B vaccine
Tajiri K, Ozawa T, Jin A, Tokimitsu Y, Minemura M, Kishi H, Sugiyama T, Muraguchi A.
Antiviral Res. 2010 Jul;87(1):40-49.
- 20) Entry of hepatitis B virus: Mechanism and new therapeutic target.
Xie Y, Zhai J, Deng Q, Tiollais P, Wang Y, Zhao M.
Pathol Biol (Paris). 2010 Aug; 58(4): 301-307.

- 21) The pre-s2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly.
Ni Y, Sonnabend J, Seitz S, Urban S.
J Virol. 2010 Apr;84(8):3879-88.
- 22) Hepatitis B Virus X protein is essential to initiate and maintain virus replication after infection.
Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M, Zoulim F, Hantz O, Protzer U.
J Hepatol. 2011 Nov; 55(5): 996-1003.
- 23) Hepatocyte polarization is essential for the productive entry of the hepatitis B virus.
Schulze A, Mills K, Weiss TS, Urban S.
Hepatology. 2012 Feb; 55(2): 373-383.
- 24) Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants.
Billioud G, Pichoud C, Parent R, Zoulim F.
J Hepatol. 2012 Jun; 56(6): 1269-1275.
- 25) Proteomic analysis of plasma membranes isolated from undifferentiated and differentiated HepaRG cells.
Sokolowska I, Dorobantu C, Woods AG, Macovei A, Branza-Nichita N, Darie CC.
Proteome Sci. 2012 Aug 2;10(1):47.
- 26) Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes.
Meier A, Mehrle S, Weiss TS, Mier W, Urban S.
Hepatology. 2012 Dec 5. doi: 10.1002/hep.26181.
- 27) Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes.
Lucifora J, Esser K, Protzer U.
Antiviral Res. 2013 Feb;97(2):195-7.
- 28) Characterization of the anti-HBV activity of HLP1-23, a human lactoferrin-derived peptide.
Florian PE, Macovei A, Lazar C, Milac AL, Sokolowska I, Darie CC, Evans RW, Roseanu A, Branza-Nichita N.
J Med Virol. 2013 May;85(5):780-8.
- 29) Replication-competent infectious hepatitis B virus vectors carrying substantially sized transgenes by redesigned viral polymerase translation.
Wang Z, Wu L, Cheng X, Liu S, Li B, Li H, Kang F, Wang J, Xia H, Ping C, Nassal M, Sun D.
PLoS One. 2013 Apr 2;8(4):e60306.
- 30) Regulation of hepatitis B virus infection by rab5, rab7, and the endolysosomal compartment.
Macovei A, Petrareanu C, Lazar C, Florian P, Branza-Nichita N.
J Virol. 2013 Jun;87(11):6415-27.
- 31) Comparative Proteomics Reveals Novel Components at the Plasma Membrane of Differentiated HepaRG Cells and Different Distribution in Hepatocyte- and Biliary-Like Cells.
Petrareanu C, Macovei A, Sokolowska I, Woods AG, Lazar C, Radu GL, Darie CC, Branza-Nichita N.
PLoS One. 2013 Aug 20;8(8):e71859
- 32) Interleukin-1 and tumor necrosis factor-alpha trigger restriction of hepatitis B virus infection via a cytidine deaminase AID.
Watashi K, Liang G, Iwamoto M, Marusawa H, Uchida N, Daito T, Kitamura K, Muramatsu M, Ohashi H, Kiyohara T, Suzuki R, Li J, Tong S, Tanaka Y, Murata K, Aizaki H, Wakita T.
J Biol Chem. 2013 Sep 11.
- 33) Cyclosporin A inhibits Hepatitis B and Hepatitis D Virus entry by Cyclophilin-independent interference with the NTCP receptor.
Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, Mier W, Mehrle S, Urban S.
J Hepatol. 2013 Nov 29. doi:pii: S0168-8278(13)00824-6. 10.1016/j.jhep.2013.11.022

- 34) Monoclonal antibodies to various epitopes of HBs antigen inhibit HBV infection.
Golsaz Shirazi F, Mohammadi H, Amiri MM, Singethan K, Xia Y, Bayat AA, Bahadori M, Rabbani H, Jeddi-Tehrani M, Protzer U, Shokri F.
J Gastroenterol Hepatol. 2013 Dec 10. doi: 10.1111/jgh.12483
- 35) Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
Iwamoto M, Watashi K, Tsukuda S, Aly HH, Fukasawa M, Fujimoto A, Suzuki R, Aizaki H, Ito T, Koiwai O, Kusuhara H, Wakita T.
Biochem Biophys Res Commun. 2014 Jan 17;443(3):808-13.
- 36) Hepatitis B and D Viruses Exploit Sodium Taurocholate Co-transporting Polypeptide for Species-specific Entry into Hepatocytes.
Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R, Sülthmann H, Urban S.
Gastroenterology. 2013 Dec 18. pii: S0016-5085(13)01808-8.
- 37) Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter NTCP.
Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, Sugiyama M, Tanaka Y, Kanai Y, Kusuhara H, Mizokami M, Wakita T.
Hepatology. 2013 Dec 21.
- 38) A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity.
Tan W, Meng Y, Li H, Chen Y, Han S, Zeng J, Huang A, Li B, Zhang Y, Guo Y.
MAbs. 2013 Nov 1;5(6):946-55. doi: 10.4161/mabs.26390.
- 39) NTCP and Beyond: Opening the Door to Unveil Hepatitis B Virus Entry.
Watashi K, Urban S, Li W, Wakita T.
Int J Mol Sci. 2014 Feb 19;15(2):2892-905.
- 40) Effect and mechanisms of curdlan sulfate on inhibiting HBV infection and acting as an HB vaccine adjuvant.
Li P, Tan H, Xu D, Yin F, Cheng Y, Zhang X, Liu Y, Wang F.
Carbohydr Polym. 2014 Sep 22;110:446-55
- 41) Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production.
Phillips S, Chokshi S, Chatterji U, Riva A, Bobardt M, Williams R, Gallay P, Naoumov NV.
Gastroenterology. 2014 Oct 8
- 42) Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level.
Peiffer KH, Akhras S, Himmelsbach K, Hassemer M, Finkernagel M, Carra G, Nuebling M, Chudy M, Niekamp H, Glebe D, Sarrazin C, Zeuzem S, Hildt E.
J Hepatol. 2014 Nov 28. pii: S0168-8278(14)00877-0.
- 43) Hepatitis B Virus Polymerase Disrupts K63-Linked Ubiquitination of STING To Block Innate Cytosolic DNA-Sensing Pathways.
Liu Y, Li J, Chen J, Li Y, Wang W, Du X, Song W, Zhang W, Lin L, Yuan Z.
J Virol. 2015 Feb 15;89(4):2287-300
- 44) Expression and characterization of myristoylated preS1-conjugated nanocages for targeted cell delivery.
Murata M, Piao JS, Narahara S, Kawano T, Hamano N, Kang JH, Asai D, Ugawa R, Hashizume M.
Protein Expr Purif. 2015 Jun;110:52-6.
- 45) HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase.
Rivière L, Gerossier L, Ducroux A, Dion S, Deng Q, Michel ML, Buendia MA, Hantz O, Neuveut C.
J Hepatol. 2015 Nov;63(5):1093-102.

46) Expression and functionality of Toll- and RIG-like receptors in **HepaRG** cells.

Luangsay S, Ait-Goughoulte M, Michelet M, Floriot O, Bonnin M, Gruffaz M, Rivoire M, Fletcher S, Javanbakht H, Lucifora J, Zoulim F, Durantel D.
J Hepatol. 2015 Nov;63(5):1077-85.

47) Early inhibition of hepatocyte innate responses by hepatitis B virus.

Luangsay S, Gruffaz M, Isorce N, Testoni B, Michelet M, Faure-Dupuy S, Maadadi S, Ait-Goughoulte M, Parent R, Rivoire M, Javanbakht H, Lucifora J, Durantel D, Zoulim F.
J Hepatol. 2015 Jul 26. pii: S0168-8278(15)00477-8.

48) Interferon- γ and Tumor Necrosis Factor- α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.

Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hösel M, Michler T, Wisskirchen K, Cheng X, Zhang K, Chou WM, Wettengel JM, Malo A, Bohne F, Hoffmann D, Eyer F, Thimme R, Falk CS, Thasler WE, Heikenwalder M, Protzer U.
Gastroenterology. 2015 Sep 25. pii: S0016-5085(15)01382-7.

49) HBV culture and infectious systems.

Hayes CN, Chayama K.
Hepatol Int. 2016 Mar 2.

50) Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus.

Isorce N, Testoni B, Locatelli M, Fresquet J, Rivoire M, Luangsay S, Zoulim F, Durantel D.
Antiviral Res. 2016 Mar 10;130:36-45.

51) Reciprocal regulation of farnesoid X receptor α activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes.

Radreau P, Porcherot M, Ramière C, Mouzannar K, Lotteau V, André P.
FASEB J. 2016 Jun 1

NEW!!

52) Unusual Features of Sodium Taurocholate Cotransporting Polypeptide as a Hepatitis B Virus Receptor.

Li J, Zong L, Sureau C, Barker L, Wands JR, Tong S.
J Virol. 2016 Aug 26;90(18):8302-13.

Hepatitis C virus

1) Inhibition of the binding of HCV serum particles to human hepatocyte by E1E2-specific D32.10 monoclonal antibody.

Ndongo N, Rechoum Y, De Sequeira S, Zoulim F, Trepo C, Drouet E, Petit MA.
J. Med. Virol. 2009 Oct; 81(10):1726-1733

2) Long-term propagation of serum hepatitis C virus with production of enveloped HCV particles in human HepaRG hepatocytes.

Ndongo-Thiam N, Berthillon P, Errazuriz E, Bordes I, De Sequeira S, Trépo C, Petit MA.
Hepatology. 2011 Aug; 54(2): 406-417.

3) Human HepaRG cells Support Long Term Propagation of Hepatitis C Virus (HCV) : Candidate Infection System for Screening Entry Inhibitors.

M-Anne Petit, Ndiém-é Ndongo, P. Berthillon, and C. Trépo
EASL 2012 **Poster**

Hepatitis Delta

1) Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulphide exchange.

Abou-Jaoudé G, Sureau C.
J Virol. 2007 Dec; 81(23): 13057-13066.

- 2) The use of hepatocytes to investigate HDV infection: the HDV/HepaRG model.
Sureau C.
Method mol Biol. 2010; 640: 463-473.
- 3) Proteoglycans act as cellular hepatitis delta virus attachment receptors.
Lamas Longarela O, Schmidt TT, Schöneweis K, Romeo R, Wedemeyer H, Urban S, Schulze A.

Other viruses

- 1) Depletion of CoREST does not improve the replication of ICP0 null mutant herpes simplex virus type 1.
Everett RD.
J Virol. 2010 Apr; 84(7): 3695-3698.
- 2) New models of hepatitis E virus replication in human and porcine hepatocyte cell lines.
Rogée S, Talbot N, Caperna T, Bouquet J, Barnaud E, Pavio N.
J Gen Virol. 2013 Mar;94(Pt 3):549-58.

Hepatocytic differentiation

- 1) Mammalian target of rapamycin activation impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular growth.
Parent R, Kolippakkam D, Booth G, Beretta L.
Cancer Res 2007 May; 67(9) :4337-4345.

Iron metabolism(HCC)

- 1) Hepatocyte iron loading capacity is associated with differentiation and repression of motility in the HepaRG cell line.
Troade MB, Glaise D, Lamirault G, Le Cunff M, Guérin E, Le Meur N, Détévaud L, Zindy P, Leroyer P, Guisle I, Duval H, Gripon P, Thérêt N, Boudjema K, Guguen-Guillouzo C, Brissot P, Léger JJ, Loréal O.
Genomics. 2006 Jan;87(1):93-103.
- 2) Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes.
Rouge P, Pires VS, Gaboriau F, Dassonville-Klimpt A, Guillon J, Nascimento SD, Leger JM, Lescoat G, Sonnet P.
J Enzyme Inhib Med Chem. 2010 Apr; 25(2): 216-227.
- 3) Effects of deferiasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
Gaboriau F, Leray AM, Ropert M, Gouffier L, Cannie I, Troade MB, Loréal O, Brissot P, Lescoat G.
Biometals. 2010 Apr; 23(2): 231-245.
- 4) Synthesis and biological properties of iron chelators based on a bis-2-(2-hydroxy-phenyl)-thiazole-4-carboxamide or -thiocarboxamide (BHPTC) scaffold.
Rodriguez-Lucena D, Gaboriau F, Rivault F, Schalk IJ, Lescoat G, Mislin GL.
Bioorg Med Chem. 2010 Jan 15;18(2):689-695
- 5) Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes. Part II.
Latxague L, Gaboriau F, Chassande O, Leger JM, Pires V, Rouge P, Dassonville-Klimpt A, Fardeau S, Jarry C, Lescoat G, Guillon J, Sonnet P.
J Enzyme Inhib Med Chem. 2011 Apr; 26(2): 204-215.
- 6) Ethanol Effect on Cell Proliferation in the Human Hepatoma HepaRG Cell Line: Relationship With Iron Metabolism.
Tuoi Do TH, Gaboriau F, Ropert M, Moirand R, Cannie I, Brissot P, Loréal O, Lescoat G.
Alcohol Clin Exp Res. 2011 Mar ; 35(3): 408-419.
- 7) Antiproliferative and iron chelating efficiency of the new bis-8-hydroxyquinoline benzylamine chelator S1 in hepatocyte cultures.
Lescoat G, Léonce S, Pierré A, Gouffier L, Gaboriau F.
Chem Biol Interact. 2012 Jan 25;195(2):165-172.
- 8) Suppression of AKT anti-apoptotic signaling by a novel drug candidate results in growth arrest and apoptosis of hepatocellular carcinoma cells.
Cuconati A, Mills C, Goddard C, Zhang X, Yu W, Guo H, Xu X, Block TM.
PLoS One. 2013;8(1):e54595.

- 9) Aberrant DNA methylation of imprinted loci in hepatocellular carcinoma and after in vitro exposure to common risk factors.
Lambert MP, Ancey PB, Esposti DD, Cros MP, Sklias A, Scoazec JY, Durantel D, Hernandez-Vargas H, Herceg Z.
Clin Epigenetics. 2015 Feb 27;7(1):15.
- 10) Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
Edeline J, Coulouarn C, Crouzet L, Pracht M, Lepareur N, Clément B, Garin E.
J Vasc Interv Radiol. 2015 Dec;26(12):1874-78.
- 11) Sp1-mediated ectopic expression of T-cell lymphoma invasion and metastasis 2 in hepatocellular carcinoma.
Yen WH, Ke WS, Hung JJ, Chen TM, Chen JS, Sun HS.
Cancer Med. 2016 Mar;5(3):465-77.

Lipid metabolism

- 1) CYP4A11 is repressed by retinoic acid in human liver cells.
Antoun J, Amet Y, Simon B, Dréano Y, Corlu A, Corcos L, Salaun JP, Plée-Gautier E.
FEBS Lett. 2006 Jun 12;580(14):3361-3367.
- 2) Highly sensitive upregulation of apolipoprotein A-IV by peroxisome proliferator-activated receptor alpha (PPARalpha) agonist in human hepatoma cells.
Nagasawa M., Akasaka Y., Ide T., Hara T., Kobayashi N., Utsumi M., Murakami K.
Biochem Pharmacol 2007 Dec 15; 74(12): 1738-1746.
- 3) CYP4F3B is induced by PGA1 in human liver cells : A regulation of the 20-HETE synthesis.
Antoun J., Goulitquer S., Amet Y., Dreano Y., Salaun J-P., Corcos L., Plee-Gautier E.
J.Lipid Res.2008 Oct ;49(10) :2135-2141.
- 4) Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells.
Anthérieu S, Rogue A, Fromenty B, Guillouzo A, Robin MA.
Hepatology. 2011 Jun; 53(6): 1895-1905.
- 5) Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes.
Rogue A, Lambert C, Jossé R, Antherieu S, Spire C, Claude N, Guillouzo A.
PLoS One. 2011 Apr 18;6(4):e18816
- 6) CYP4F3B Expression is Associated with Differentiation of HepaRG Human Hepatocytes and Unaffected by Fatty Acid Overload.
Madec S, Cerec V, Plee-Gautier E, Antoun J, Glaise D, Salaun JP, Guguen-Guillouzo C, Corlu A.
Drug Metab Dispos. 2011 Oct; 39(10): 1987-1996.
- 7) The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism.
Samanez CH, Caron S, Briand O, Dehondt H, Duplan I, Kuipers F, Hennuyer N, Clavey V, Staels B.
Arch Physiol Biochem. 2012 Jul; 118(3): 102-111.
- 8) PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A, Anthérieu S, Vluugens A, Umbdenstock T, Claude N, de la Moureyre-Spire C, Weaver RJ, Guillouzo A.
Toxicol Appl Pharmacol. 2014 Feb 15. pii: S0041-008X(14)00038-6.
- 9) Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175.
Piemontese L, Fracchiolla G, Carrieri A, Parente M, Laghezza A, Carbonara G, Sblano S, Tauro M, Gilardi F, Tortorella P, Lavecchia A, Crestani M, Desvergne B, Liodice F.
Eur J Med Chem. 2015 Jan 27;90:583-94.

NEW!!

- 10) Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis.
Tolosa L, Gómez-Lechón MJ, Jiménez N, Hervás D, Jover R, Donato MT.
Toxicol Appl Pharmacol. 2016 Jul 1;302:1-9.

NEW!!

- 11) The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells.
Nunn AD, Scopigno T, Pediconi N, Levrero M, Hagman H, Kiskis J, Enejder A.
Sci Rep. 2016 Jun 20;6:28025

NEW!!

- 12) Bisphenol A induces steatosis in HepaRG cells using a model of perinatal exposure.
Bucher S, Jalili P, Le Guillou D, Begriche K, Rondel K, Martinais S, Zalko D, Corlu A, Robin MA, Fromenty B.
Environ Toxicol. 2016 Jun 20.

Insulin secretion

- 1) Forced expression of PDX-1 gene makes hepatoma cells to acquire glucose-responsive insulin secretion while maintaining hepatic characteristic.
Hashimoto H, Higuchi Y, Kawai K.
Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):20-9.

■お問い合わせは・・・

 株式会社 ケー・イー・シー
<http://www.kacnet.co.jp/>

試薬営業グループ

〒110-0005
東京都台東区上野 1 丁目 4-4 藤井ビル 3F
TEL 03-5807-7162
e-mail: shiyaku-info@kacnet.co.jp